JPMorgan (NYSE:JPM) analysts have projected that REDEFINE 1 will demonstrate CagriSema’s capability to deliver an average weight reduction of 25% from baseline, measured on an intention-to-treat (ITT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback